Arkansas AG sues 13 drugmakers + a data firm over 340B — the first time a state goes on OFFENSE under its own 340B shield law, with the state health-center association standing beside him
Arkansas Attorney General Tim Griffin filed suit July 22, 2026 in Polk County Circuit Court against 22 defendants — 13 drug manufacturers and related entities including Pfizer, Bristol Myers Squibb, AstraZeneca, Eli Lilly, Sanofi and Novo Nordisk, plus data-management firm Second Sight Solutions, LLC — alleging violations of Act 1103 of 2021 and the Arkansas Deceptive Trade Practices Act.
WHY THIS IS STRUCTURALLY DIFFERENT FROM EVERY OTHER 340B CASE WE TRACK: in Washington, North Dakota, Missouri, West Virginia/Maryland, Vermont and New Mexico, the pattern is a MANUFACTURER SUING A STATE to block a contract-pharmacy law. This is the inverse — a state attorney general enforcing an enacted 340B shield law against manufacturers, in state court, seeking $10,000 per violation with total civil penalties the coverage puts above $1 billion, plus an injunction barring the restrictions.
Act 1103 is the strongest possible platform for it: the 8th Circuit upheld the law and the Supreme Court declined to review it. THE ALLEGED MECHANISM IS THE PART FQHC LEADERS SHOULD READ: the state says manufacturers, unable to restrict contract pharmacies directly, pivoted to conditions Act 1103 does not expressly forbid — chiefly REQUIRING COVERED ENTITIES TO HAND OVER CLAIMS OR MEDICAL DATA to receive 340B pricing — and that each manufacturer adopted near-identical restrictions with little variance.
That is the same play as the already-tracked Eli Lilly five-day claims-data ultimatum. Community Health Centers of Arkansas CEO Lanita White appeared at the announcement alongside Griffin.
HONEST LIMITS: a complaint is an allegation, not a finding; no ruling exists; and the $1B figure is a sought-penalty ceiling, not a recovery. Its value to California is precedential rather than immediate — it tests whether a state 340B shield law is worth anything without an enforcer, which is the open question hanging over AB 1460.
Key takeaways
- Every other state 340B case we track is a manufacturer suing a state. This is the first state attorney general suing manufacturers under an enacted 340B shield law — the enforcement question, not the enactment question.
- The alleged workaround is claims-data and medical-data conditions on 340B pricing — the same mechanism as the tracked Eli Lilly ultimatum. If your organization has received a data-submission demand tied to 340B access, this complaint describes it as an unlawful restriction.
- For California this is precedent, not relief: it tests whether a 340B shield law means anything without an enforcer — the open question behind AB 1460. A complaint is an allegation; there is no ruling, and the $1B figure is a sought ceiling.
Primary source
Arkansas AdvocateSource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
This story will move — get the follow-up
The weekly FQHC Intel Brief traces every claim to a primary source, like the one above. Free.
You are signing up for the newsletter you choose, a short welcome sequence, occasional product updates, and one-click unsubscribe. We do not sell your email. Privacy Policy · Do Not Sell/Share
FQHC Talent. (2026, July 22). Arkansas AG sues 13 drugmakers + a data firm over 340B — the first time a state goes on OFFENSE under its own 340B shield law, with the state health-center association standing beside him. Primary source: Arkansas Advocate. Retrieved July 28, 2026, from https://www.fqhctalent.com/intel/arkansas-ag-sues-22-drugmakers-340b-act-1103-july-2026
More in Legislation
Jul 24
HHS strips disparate-impact liability out of its Title VI regulations — final rule, effective the day it published, no comment period; 45 CFR part 80 binds every Section 330 grantee
Jul 16
CY2027 Physician Fee Schedule Proposed Rule Lands — CMS Proposes the FQHC PPS Base Rate Rise to $212.91 (+2.5%), Comments Close September 14
Jul 1
8th Circuit Rejects Novartis's Bid to Block Missouri's 340B Contract-Pharmacy Law — Another State Shield Survives a Manufacturer Challenge
Jun 30
AHA Files En Banc Review Petition After 4th Circuit Blocks WV 340B Contract Pharmacy Law — Decision Expected Mid-May